Icahn School of Medicine at Mount Sinai
New York, New York
Assistant Professor, Department of Oncological Sciences
American Association of Cancer Research
Understanding the characteristics of bone niches that promote metastasis.
Metastasis is responsible for virtually all breast cancer-related deaths. While cancer cells can metastasize to various sites, some tissues tend to play an essential role in the process. Bone is the most common site of metastasis in breast cancer. Additionally, there is a high association between multi-organ metastasis and the presence of bone metastases, suggesting that cancer cells first metastasize to bone then can migrate to other organs and form new metastases. In other words, bone metastasis may fuel metastasis expansion. In previous studies, Dr. Bado and colleagues identified a central role of a bone stem cell factor, FGF2, in mediating epigenetic reprogramming in bone metastasis and sustaining dormant tumor cells (DTCs). Dr. Bado aims to investigate niches in bone that promote survival of DTCs and ultimately lead to therapeutic resistance and metastatic progression.
For his AACR award supported by BCRF, Dr. Bado will profile and characterize pro-survival niches that are involved in bone metastasis. He will first establish a bone-specific multiplex imaging panel to characterize FGF2 “hotspots” in bone. Next, metastasis stages will be evaluated with an emphasis on DTC states. Finally, Dr. Bado aims to identify alternative therapeutic strategies to eliminate DTCs with metastasis initiation potential. Overall, this project will improve our understanding of long-term dormancy while informing strategies to prevent recurrence in breast cancer.
Igor Bado, PhD is an Assistant Professor in the Department of Oncological Sciences at the Icahn School of Medicine at Mount Sinai. Dr. Bado obtained his PhD at the University of Houston and completed his postdoctoral studies at Baylor College of Medicine. Dr. Bado works on various mechanisms of breast cancer metastasis and therapeutic resistance. In his recent studies, he helped identify the FGFR/EZH2 axis as a central driver of epigenetic reprogramming in the early stage of bone metastasis. Dr. Bado has received multiple awards and honors and his laboratory is funded by the National Cancer Institute. His research focuses on understanding the interconnection between breast cancer metastases and their microenvironment using a multidisciplinary approach.
Please remember BCRF in your will planning. Learn More
Breast Cancer Research Foundation28 West 44th Street, Suite 609, New York, NY 10036
General Office: 646-497-2600 | Toll Free: email@example.com | BCRF is a 501 (c)(3) | EIN: 13-3727250